NewAmsterdam Pharma Company N.V.
Every calculator, already run for NAMS
Open the full toolkit →You have the numbers on NAMS. Get the argument.
A written report on which of these readings actually decide the outcome for NewAmsterdam Pharma Company N.V., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
16 analysts covering NAMSAnalyst Price Target Disagreement for NewAmsterdam Pharma Company N.V.
Wall Street's bull case implies +119% from the current price; the bear case implies +38%. A 80% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for NAMS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NAMS — frequently asked
Is NAMS a buy right now?
Wall Street's consensus rating on NewAmsterdam Pharma Company N.V. is Strong Buy across 16 analysts, with a mean price target of $51.96 (+87% vs. the current $27.78). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is NAMS's next earnings date?
NewAmsterdam Pharma Company N.V. is next scheduled to report earnings around Nov 4, 2026. A full NAMS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for NewAmsterdam Pharma Company N.V.?
Analysts covering NewAmsterdam Pharma Company N.V. (NAMS) range from a bear-case target of $38.45 to a bull-case high of $60.71, with a mean consensus target of $51.96 across 15 analysts. The spread of $22.26 (80% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare NewAmsterdam Pharma Company N.V. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For NewAmsterdam Pharma Company N.V.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full NAMS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on NewAmsterdam Pharma Company N.V., in minutes. 3 free reports included with every account — no credit card required.